JP2006524491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524491A5 JP2006524491A5 JP2006503972A JP2006503972A JP2006524491A5 JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5 JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5
- Authority
- JP
- Japan
- Prior art keywords
- tropomyosin
- compound
- activity
- binding
- cell surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005937 Tropomyosin Human genes 0.000 claims 35
- 108010030743 Tropomyosin Proteins 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 28
- 238000000034 method Methods 0.000 claims 23
- 230000000694 effects Effects 0.000 claims 11
- 102000018697 Membrane Proteins Human genes 0.000 claims 7
- 108010052285 Membrane Proteins Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 230000001413 cellular effect Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108091030071 RNAI Proteins 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 102000001708 Protein Isoforms Human genes 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 108091006146 Channels Proteins 0.000 claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 2
- 101150048952 TPM-1 gene Proteins 0.000 claims 2
- 101150043385 Tpm3 gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000021164 cell adhesion Effects 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102000034285 signal transducing proteins Human genes 0.000 claims 2
- 108091006024 signal transducing proteins Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 108091027757 Deoxyribozyme Proteins 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 102000004878 Gelsolin Human genes 0.000 claims 1
- 108090001064 Gelsolin Proteins 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 claims 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 claims 1
- 101000830781 Homo sapiens Tropomyosin alpha-4 chain Proteins 0.000 claims 1
- 101000851892 Homo sapiens Tropomyosin beta chain Proteins 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 claims 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 claims 1
- 102100024944 Tropomyosin alpha-4 chain Human genes 0.000 claims 1
- 102100036471 Tropomyosin beta chain Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 102000006783 calponin Human genes 0.000 claims 1
- 108010086826 calponin Proteins 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- -1 enigma Proteins 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901316A AU2003901316A0 (en) | 2003-03-21 | 2003-03-21 | Regulation of cell surface proteins |
| PCT/AU2004/000358 WO2004082690A1 (en) | 2003-03-21 | 2004-03-22 | Regulation of cell surface proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524491A JP2006524491A (ja) | 2006-11-02 |
| JP2006524491A5 true JP2006524491A5 (enExample) | 2007-05-24 |
Family
ID=31500359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503972A Withdrawn JP2006524491A (ja) | 2003-03-21 | 2004-03-22 | 細胞表面タンパク質の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060263781A1 (enExample) |
| EP (1) | EP1622626A1 (enExample) |
| JP (1) | JP2006524491A (enExample) |
| CN (1) | CN1761472A (enExample) |
| AU (1) | AU2003901316A0 (enExample) |
| CA (1) | CA2517186A1 (enExample) |
| WO (1) | WO2004082690A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5140218B2 (ja) | 2001-09-14 | 2013-02-06 | 有限会社コヒーレントテクノロジー | 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法 |
| US8062500B2 (en) | 2001-12-05 | 2011-11-22 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (ORP) water |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| AU2006226750B2 (en) | 2005-03-23 | 2012-07-19 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| MX2007013774A (es) | 2005-05-02 | 2008-01-29 | Oculus Innovative Sciences Inc | Metodo para utilizar solucion de agua con potencial oxido reductor en aplicaciones dentales. |
| WO2007085018A2 (en) | 2006-01-20 | 2007-07-26 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| DK2135081T3 (da) * | 2007-04-16 | 2013-03-11 | Momenta Pharmaceuticals Inc | Fremgangsmåder i forbindelse med celleoverfladeglycosylering |
| CN102480972B (zh) | 2009-06-15 | 2014-12-10 | 奥古露丝创新科学公司 | 含有次氯酸的溶液及其使用方法 |
| CN103228787B (zh) * | 2010-09-28 | 2017-06-23 | 阿贝拉生物科学公司 | 用于分泌性蛋白表达的融合蛋白 |
| AU2019370363B2 (en) * | 2018-10-30 | 2025-07-10 | University Of Florida Research Foundation, Incorporated | Amino acid compositions and methods for treating cystic fibrosis |
| CN111175431A (zh) * | 2020-01-15 | 2020-05-19 | 上海林志生物科技有限公司 | 一种用于肺癌诊断的靶蛋白及其用途、试剂盒 |
| CN115060898B (zh) * | 2021-07-01 | 2025-08-12 | 浙江大学 | 一种检测抗原肌球蛋白1-IgG抗体的试剂盒 |
-
2003
- 2003-03-21 AU AU2003901316A patent/AU2003901316A0/en not_active Abandoned
-
2004
- 2004-03-22 JP JP2006503972A patent/JP2006524491A/ja not_active Withdrawn
- 2004-03-22 WO PCT/AU2004/000358 patent/WO2004082690A1/en not_active Ceased
- 2004-03-22 CN CNA2004800077366A patent/CN1761472A/zh active Pending
- 2004-03-22 EP EP04722197A patent/EP1622626A1/en not_active Withdrawn
- 2004-03-22 CA CA002517186A patent/CA2517186A1/en not_active Abandoned
- 2004-03-22 US US10/549,301 patent/US20060263781A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2569431B1 (en) | Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity | |
| CN101573446B (zh) | 针对中期因子的适体及其应用 | |
| JP6141018B2 (ja) | 炎症性障害を治療するための分子 | |
| CN112040988A (zh) | 修饰的aav衣壳多肽用于治疗肌肉疾病 | |
| Xia et al. | Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47 | |
| JP2006524491A5 (enExample) | ||
| Zhao et al. | Nonenzymatic lysine D-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses | |
| CN115175685B (zh) | 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸 | |
| JP2010521978A5 (enExample) | ||
| Yang et al. | Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA | |
| Gambari et al. | Decoy oligodeoxyribonucleotides and peptide nucleic acids–DNA chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa | |
| Momin et al. | Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation | |
| CN108642069A (zh) | 一种三疣梭子蟹comt基因及其应用 | |
| McCollum et al. | Safety and biodistribution of nanoligomers targeting the SARS-CoV-2 genome for the treatment of COVID-19 | |
| JP2010536365A5 (enExample) | ||
| ITRM950273A1 (it) | Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni | |
| WO2016079321A1 (en) | Antagonists of setdb2 for use in the therapy of infectious diseases | |
| US20240392295A1 (en) | Treatment of mst1 related diseases and disorders | |
| JP2007525203A5 (enExample) | ||
| Uemura et al. | Short Polymers of Arginine Rapidly Translocate Into Vascular Cells Effects on Nitric Oxide Synthesis | |
| WO2005104785A3 (en) | Methods and compositions for specifically targeting human hepatocellular carcinoma cells | |
| Fujiwara et al. | Spatial organizations of heterochromatin underpin nuclear structural integrity of ventricular cardiomyocytes against mechanical stress | |
| US12442002B2 (en) | RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use | |
| JP2006516888A5 (enExample) | ||
| JP2005536535A5 (enExample) |